<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099632</url>
  </required_header>
  <id_info>
    <org_study_id>A5207</org_study_id>
    <secondary_id>10127</secondary_id>
    <secondary_id>ACTG A5207</secondary_id>
    <secondary_id>MOMS</secondary_id>
    <nct_id>NCT00099632</nct_id>
  </id_info>
  <brief_title>Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy</brief_title>
  <official_title>Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infected pregnant women may take single-dose nevirapine (SD NVP) prior to giving birth to
      prevent mother-to-child transmission (MTCT) of HIV. However, SD NVP may cause NVP resistance
      in the mother, potentially ruling out some treatment options in the future. The purpose of
      this study is to determine which of three anti-HIV drug regimens most effectively reduces the
      development of maternal NVP resistance in HIV infected pregnant women. The effectiveness of
      short-term (7 day therapy) versus long-term (21-day therapy) regimens will also be compared.

      The study hypotheses are: 1) intrapartum SD NVP with a 21-day course of antiretroviral
      therapy (ART) results in less frequent selection of NVP-resistant HIV-1 variants than
      intrapartum SD NVP with a 7-day course of ART, and 2) a 7- or 21-day course of
      lamivudine/zidovudine (3TC/ZDV), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), or
      lopinavir/ritonavir (LPV/r) following SD NVP will not select nucleoside reverse transcriptase
      inhibitor (NRTI)- or protease inhibitor (PI)- resistant HIV-1 variants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A major disadvantage of giving SD NVP is the potential for maternal development of NVP
      resistance and additional resistance to other nonnucleoside reverse transcriptase inhibitors
      (NNRTI) in the mother; as a result, future treatment options may be limited for these HIV
      infected women. The purpose of the study is to determine which of three ART regimens most
      effectively deters the development of maternal NVP resistance in HIV infected pregnant women
      postpartum. This study also compared the effectiveness of short-term versus long-term ART in
      discouraging the development of maternal NVP resistance.

      Some mothers in this study received ZDV monotherapy prior to SD NVP administration;
      initiation of ZDV monotherapy was at the discretion of the site investigator and was be
      provided by this study. Randomization was stratified by receipt of ZDV monotherapy during the
      pregnancy.

      Prior to labor, mothers were randomly assigned to receive SD NVP at the onset of labor and
      one of three postpartum ART regimens: 3TC/ZDV, FTC/TDF, and LPV/r. In addition, participants
      were randomly assigned to receive 7 or 21 days of their assigned postpartum treatment.

      Mothers were followed for 96 weeks following delivery; there were 11 study visits for mothers
      during the study. At the onset of labor, medical and medication history, a targeted physical
      exam, and an obstetrical exam occurred. Additional physical exams occurred on Day 1 and Weeks
      1 and 3. Blood collection occurred at 8 study visits between Weeks 3 and 96. Infants were
      followed for up to 96 weeks after birth; there were 8 study visits for infants during the
      study. Infants who had ever been breastfed had study visits at Weeks 16, 24, 48, and 96, and
      at about 1 and 2 years of age. A physical exam, medication history, and blood collection
      occurred at each infant visit. Mothers and infants could be prescribed continuing ART, but
      such ART was be provided by this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping</measure>
    <time_frame>2 and 6 weeks after completion of treatment</time_frame>
    <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.
10 participants who did not have resistance samples available were excluded from the primary endpoint analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.</measure>
    <time_frame>2 and 6 weeks after completion of treatment</time_frame>
    <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.</measure>
    <time_frame>2 and 6 weeks after completion of treatment</time_frame>
    <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12</measure>
    <time_frame>From first day of study treatment to week 12</time_frame>
    <description>Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.
Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Prematurely</measure>
    <time_frame>From first day of study treatment to last day of study treatment (up to 21 days)</time_frame>
    <description>participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">484</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>7-day 3TC/ZDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>21-day 3TC/ZDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-day FTC/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>21-day FTC/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-day LPV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>21-day LPV/r</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir Disoproxil Fumarate</intervention_name>
    <description>200mg/300mg as one tablet taken orally once daily</description>
    <arm_group_label>7-day FTC/TDF</arm_group_label>
    <arm_group_label>21-day FTC/TDF</arm_group_label>
    <other_name>FTC/TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine/Zidovudine</intervention_name>
    <description>150mg/300mg as one tablet taken orally twice daily</description>
    <arm_group_label>7-day 3TC/ZDV</arm_group_label>
    <arm_group_label>21-day 3TC/ZDV</arm_group_label>
    <other_name>3TC/ZDV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/Ritonavir</intervention_name>
    <description>133.3mg/33.3mg as three capsules taken orally twice daily</description>
    <arm_group_label>7-day LPV/r</arm_group_label>
    <arm_group_label>21-day LPV/r</arm_group_label>
    <other_name>LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose Nevirapine</intervention_name>
    <description>one 200 mg tablet taken orally</description>
    <arm_group_label>7-day 3TC/ZDV</arm_group_label>
    <arm_group_label>21-day 3TC/ZDV</arm_group_label>
    <arm_group_label>7-day FTC/TDF</arm_group_label>
    <arm_group_label>21-day FTC/TDF</arm_group_label>
    <arm_group_label>7-day LPV/r</arm_group_label>
    <arm_group_label>21-day LPV/r</arm_group_label>
    <other_name>SD NVP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Mothers:

          -  HIV-1 infected

          -  CD4 count 250 cells/mm3 or greater within 30 days of study entry

          -  The following laboratory values obtained within 30 days prior to study entry: absolute
             neutropil count &gt;= 750/mm3; hemoglobin &gt;= 8.0 g/dL; platelet count &gt;= 50,000/mm3;
             calculated creatinine clearance (Cockcroft-Gault formula) &gt; 60 mL/min; AST(SGOT) and
             ALT(SGPT) &lt; 5 x ULN; total bilirubin &lt; 1.5 X ULN.

          -  Pregnant with a viable fetus at 28 to 38 weeks gestation at study entry.

          -  Willing to give birth to baby in a hospital or clinic

          -  Written informed consent from parent or guardian, if applicable

        Exclusion Criteria for Mothers:

          -  Any ART, including single-dose NVP, prior to study entry. Mothers who receive ZDV
             monotherapy prior to labor under the supervision of the site investigator are not
             excluded.

          -  Known allergy or sensitivity to study drugs or their formulations

          -  Current drug or alcohol abuse that may interfere with the study

          -  Serious illness requiring systemic treatment or hospitalization. Participants who
             complete therapy or are clinically stable on therapy for at least 14 days prior to
             study entry are not excluded.

          -  Hepatitis B surface antigen positive within 180 days prior to study entry

          -  Active tuberculosis infection requiring treatment

          -  Prior enrollment in this study

          -  Expect to use ART, except ZDV monotherapy, prior to onset of labor

          -  Expect to use ART other than study medications from delivery to 9 weeks postpartum
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Hitti, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics/Gynecology, Perinatal Medicine, University of Washington Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah McMahon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Infectious Diseases, Department of Medicine, University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS</name>
      <address>
        <city>Port-au-Prince</city>
        <zip>6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byramjee Jeejeebhoy Government Medical College CRS</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chennai Antiviral Research and Treatment (CART) CRS</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blantyre CRS</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits Helen Joseph Hospital CRS (Wits HJH CRS)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durban International CRS</name>
      <address>
        <city>Westville</city>
        <state>KwaZulu-Natal</state>
        <zip>3610</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical CRS</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Center (JCRC)/Kampala CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Haiti</country>
    <country>India</country>
    <country>Malawi</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002 Jul 15;186(2):181-8. Epub 2002 Jun 26.</citation>
    <PMID>12134253</PMID>
  </reference>
  <reference>
    <citation>Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002 Apr-Jun;4(2):59-63. Review.</citation>
    <PMID>12152519</PMID>
  </reference>
  <reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M; Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004 Jul 15;351(3):229-40. Epub 2004 Jul 9.</citation>
    <PMID>15247339</PMID>
  </reference>
  <reference>
    <citation>Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005 Jan 3;19(1):63-7. Erratum in: AIDS. 2007 Jul 31;21(12):1671.</citation>
    <PMID>15627034</PMID>
  </reference>
  <reference>
    <citation>Sullivan JL. Prevention of mother-to-child transmission of HIV--what next? J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S67-72. Review.</citation>
    <PMID>14562860</PMID>
  </reference>
  <results_reference>
    <citation>McMahon D, Noel F, Zheng L, Kabanda J, Halvas E, Taulo F, Kumarasamy N, Wallis C, Hughes M, Mellors J. Suppression of NVP Resistance with 7- vs 21-day ARV Regimens after Single-dose NVP: Results of A5207. Presented at 18th Conference on Retroviruses &amp; Opportunistic Infections (CROI 11) on 03/01/2011 at Boston, MA</citation>
  </results_reference>
  <results_reference>
    <citation>Hong F, Halvas E, Chan E, Zheng L, Hughes M, Hitti J, McMahon D, Mellors J. Suppression of Minor NVP-Resistant Variants With 7- vs. 21-Day Antiretroviral Regimens After Single Dose Nevirapine. Presented at 20th Anniversary of the International Workshop on HIV &amp; Hepatitis Virus Drug Resistance and Curative Strategies on Jun 9, 2011, Los Cabos, Mexico</citation>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2004</study_first_submitted>
  <study_first_submitted_qc>December 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2004</study_first_posted>
  <results_first_submitted>December 6, 2011</results_first_submitted>
  <results_first_submitted_qc>January 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2012</results_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants were recruited at 8 sites: 2 from South Africa, 2 from India, and 1 each from Haiti, Uganda, Tanzania, and Malawi, between January 2007 to October 2009.</recruitment_details>
      <pre_assignment_details>62 participants who randomized but did not start study treatment were excluded from the analysis. These 62 participants were either off study prior to delivery or delivered on study but did not take any dose of study treatment.
All the analyses were restricted to the 422 women who received study treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
          <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
        </group>
        <group group_id="P2">
          <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
          <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
        </group>
        <group group_id="P3">
          <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
        </group>
        <group group_id="P4">
          <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
        </group>
        <group group_id="P5">
          <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
          <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
        </group>
        <group group_id="P6">
          <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
          <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="71"/>
                <participants group_id="P6" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
          <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
        </group>
        <group group_id="B2">
          <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
          <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
        </group>
        <group group_id="B3">
          <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
        </group>
        <group group_id="B4">
          <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
          <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
        </group>
        <group group_id="B5">
          <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
          <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
        </group>
        <group group_id="B6">
          <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
          <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="68"/>
            <count group_id="B3" value="75"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="71"/>
            <count group_id="B6" value="68"/>
            <count group_id="B7" value="422"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="6"/>
                    <measurement group_id="B2" value="27" spread="5"/>
                    <measurement group_id="B3" value="26" spread="5"/>
                    <measurement group_id="B4" value="26" spread="5"/>
                    <measurement group_id="B5" value="27" spread="6"/>
                    <measurement group_id="B6" value="26" spread="5"/>
                    <measurement group_id="B7" value="27" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 13 and 19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 20 and 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 30 and 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="68"/>
                    <measurement group_id="B7" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Haiti</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tanzania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malawi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at NVP dosing, Continuous</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="2"/>
                    <measurement group_id="B2" value="39" spread="2"/>
                    <measurement group_id="B3" value="38" spread="2"/>
                    <measurement group_id="B4" value="38" spread="3"/>
                    <measurement group_id="B5" value="38" spread="2"/>
                    <measurement group_id="B6" value="38" spread="2"/>
                    <measurement group_id="B7" value="38" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening CD4 count Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>250-349 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>350-499 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=500 cells/mm^3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening CD4 count Continuous</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="538" spread="244"/>
                    <measurement group_id="B2" value="585" spread="215"/>
                    <measurement group_id="B3" value="537" spread="186"/>
                    <measurement group_id="B4" value="545" spread="191"/>
                    <measurement group_id="B5" value="505" spread="205"/>
                    <measurement group_id="B6" value="566" spread="249"/>
                    <measurement group_id="B7" value="545" spread="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening HIV-1 RNA Categorical</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>401-999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1000-9999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10000-99999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100000-749999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=750000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening HIV-1 RNA Continuous</title>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.50" spread="1.01"/>
                    <measurement group_id="B2" value="3.55" spread="0.90"/>
                    <measurement group_id="B3" value="3.54" spread="0.82"/>
                    <measurement group_id="B4" value="3.50" spread="0.88"/>
                    <measurement group_id="B5" value="3.63" spread="0.90"/>
                    <measurement group_id="B6" value="3.66" spread="0.92"/>
                    <measurement group_id="B7" value="3.56" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Actual ZDV exposure during pregnancy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping</title>
        <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.
10 participants who did not have resistance samples available were excluded from the primary endpoint analysis.</description>
        <time_frame>2 and 6 weeks after completion of treatment</time_frame>
        <population>412 women with primary endpoint results available</population>
        <group_list>
          <group group_id="O1">
            <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O2">
            <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O3">
            <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
          </group>
          <group group_id="O4">
            <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
          </group>
          <group group_id="O5">
            <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
          </group>
          <group group_id="O6">
            <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping</title>
          <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.
10 participants who did not have resistance samples available were excluded from the primary endpoint analysis.</description>
          <population>412 women with primary endpoint results available</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Compare proportion of women with new NNRTI-resistant variants between treatment durations (7-day vs. 21 day), pooled over ARV regimens (3TC/ZDV, FTC/TDF, and LPV/r), stratified by ARV regimen and the actual receipt of antenatal ZDV</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by ARV regimen and the actual receipt of antenatal ZDV</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Compare proportion of women with new NNRTI-resistant variants among ARV regimens (3TC/ZDV vs. FTC/TDF vs. LPV/r), pooled over treatment durations 7-day and 21-day, stratified by treatment duration and the actual receipt of antenatal ZDV</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test stratified by treatment duration and the actual receipt of antenatal ZDV</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.</title>
        <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed.</description>
        <time_frame>2 and 6 weeks after completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O2">
            <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O3">
            <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
          </group>
          <group group_id="O4">
            <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
          </group>
          <group group_id="O5">
            <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
          </group>
          <group group_id="O6">
            <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.</title>
          <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.</title>
        <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed.</description>
        <time_frame>2 and 6 weeks after completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O2">
            <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O3">
            <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
          </group>
          <group group_id="O4">
            <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
          </group>
          <group group_id="O5">
            <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
          </group>
          <group group_id="O6">
            <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.</title>
          <description>For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12</title>
        <description>Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.
Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death</description>
        <time_frame>From first day of study treatment to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O2">
            <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O3">
            <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
          </group>
          <group group_id="O4">
            <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
          </group>
          <group group_id="O5">
            <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
          </group>
          <group group_id="O6">
            <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
          </group>
        </group_list>
        <measure>
          <title>Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12</title>
          <description>Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.
Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Study Treatment Prematurely</title>
        <description>participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively.</description>
        <time_frame>From first day of study treatment to last day of study treatment (up to 21 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>7-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O2">
            <title>21-day Lamivudine/Zidovudine (3TC/ZDV)</title>
            <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.</description>
          </group>
          <group group_id="O3">
            <title>7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.</description>
          </group>
          <group group_id="O4">
            <title>21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)</title>
            <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.</description>
          </group>
          <group group_id="O5">
            <title>7-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.</description>
          </group>
          <group group_id="O6">
            <title>21-day Lopinavir/Ritonavir (LPV/r)</title>
            <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Treatment Prematurely</title>
          <description>participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="67"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first treatment date to 12 weeks of follow up.</time_frame>
      <desc>Expedited adverse event(AE) reporting followed intensive DAIDS Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and &gt;=3 grade 3 AEs defined by the &quot;DAIDS Table for Grading the Severity of Adult and Pediatric AEs&quot;.</desc>
      <group_list>
        <group group_id="E1">
          <title>7-day 3TC/ZDV</title>
          <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV</description>
        </group>
        <group group_id="E2">
          <title>21-day 3TC/ZDV</title>
          <description>SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV</description>
        </group>
        <group group_id="E3">
          <title>7-day FTC/TDF</title>
          <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF</description>
        </group>
        <group group_id="E4">
          <title>21-day FTC/TDF</title>
          <description>SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF</description>
        </group>
        <group group_id="E5">
          <title>7-day LPV/r</title>
          <description>SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r</description>
        </group>
        <group group_id="E6">
          <title>21-day LPV/r</title>
          <description>SD NVP and LPV/r provided at onset of active labor, followed by 21 days of LPV/r</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Uterine rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Intra-uterine death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>(617) 432-2829</phone>
      <email>CBAR.ClinicalTrials.gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

